HLA-C and myeloid sarcoma: The strategy using soluble peptide/MHC complexes as antigen-specific modulators–due to their specificity for cognate TCR–is more desirable than anti-CD3 or anti-TCR treatment strategy, as global depletion and potent activation of T cells by these antibodies demonstrated less impressive results in MS patients and EAE animal models during initial trials [25], [26].